Abstract. – OBJECTIVE: Berberine is a plant alkaloid known to exert positive metabolic effects. Human studies have confirmed its ability to improve the lipid and glycemic profile. This study aimed to evaluate the potential benefit of oral supplementation of Berberine Phytosome™ (2 tablets/day, 550 mg/tablet) on the metabolic profile of subjects with impaired fasting blood glucose (IFG).

PATIENTS AND METHODS: A total of 49 overweight subjects, 28 females and 21 males, were randomly assigned to either the supplemented group (n=24) or placebo (n=25). We considered glycemia as the primary endpoint and total cholesterol, high-density lipoprotein (HDL), total cholesterol/HDL, low-density lipoprotein (LDL), LDL/HDL, triglycerides, insulin, glycated hemoglobin, Homeostasis Model Assessment (HOMA), ApoA, ApoB, ApoB/ApoA, androgen suppression treatment (AST), alternative lengthening of telomeres (ALT), gamma-glutamyl transferase (GGT), creatinine, and body composition by Dual-energy X-ray Absorptiometry (DXA) as secondary endpoints. These parameters have been assessed at baseline, after 30 days, and after 60 days.

RESULTS: After two months of treatment, through the use of linear mixed effect models, a statistically significant difference between supplemented and placebo groups was observed for glycemia [β=-0.2495, 95% C.I. (-0.47; -0.06), p=0.004], insulin [β=-1.78, 95% C.I. (-2.87; -0.66), p=0.009], ApoB/ApoA [β=-0.08, 95% C.I. (-0.13; -0.03), p=0.004], Visceral adipose tissue (VAT) [β=-91.50, 95% C.I. (-132.60; -48.19), p<0.0001] and fat mass [β=-945.56, 95% C.I. (-1,424.42; -441.57), p=0.004].

CONCLUSIONS: The use of berberine had no adverse events, supporting its use as a natural alternative to pharmacological therapies in the case of IFG.

Key Words: Berberine, Impaired fasting blood glucose, Phytosome™, Insulin, Body composition.

Introduction

Berberine is a plant alkaloid that has long been used in Indian Ayurvedic and traditional Chinese medicine. The use of berberine is encouraged in the prevention and management of metabolic and cardiovascular diseases, given its anti-inflammatory and antioxidant activities and neuro- and cardioprotective effects demonstrated in vitro and animal models. The common factor in many metabolic and cardiovascular diseases is a chronic, low-inflammatory state due to increased oxidative stress and the expression of pro-inflammatory cytokines. Berberine modulates the cellular...
Berberine phospholipid for impaired fasting blood glucose (IFG)

signaling pathways involved in these processes. Berberine exerts a potent anti-inflammatory effect by reducing the secretion of inflammatory cytokines.

The hypoglycemic action of berberine is complex and is due to different mechanisms, such as the reduction of intestinal glucose absorption, the increase in glucose uptake in the liver and muscles, the modulation of the intestinal microbiota, the removal of gluconeogenesis, and the stimulation of glycogenesis.

In pancreatic β-cells, berberine acts with an incretin-like mechanism to stimulate the glucagon-like peptide one receptor (GLP-1), thus leading to an increase in insulin secretion. In muscle cells and adipocytes, berberine increases insulin receptor expression. It triggers 5' adenosine monophosphate-activated protein kinase (AMPK), which in turn activates the translocation of GLUT-4 transporters at the membrane level, resulting in increased glucose absorption.

Berberine is absorbed in the gastrointestinal tract with low efficiency (<1%). In humans, administration of a single dose of 500 mg generates plasma levels of 0.07±0.1 nM. At the same time, it reaches the maximum concentration of 4.0±2.0 nM after three months of chronic administration at a dosage of 15 mg/kg. The low efficiency of berberine transport in the blood is mainly due to poor oral bioavailability, caused by several factors. First, berberine, at low pH levels, tends to self-aggregate. Secondly, berberine is a substrate of P-glycoprotein (Pg-P) that causes its outflow to the intestinal lumen, further limiting absorption. Berberine is metabolized in the liver, where it undergoes a demethylation reaction in phase I, followed by conjugation with glucuronic acid or sulphuric acid to form phase II metabolites of a polar nature that are readily excreted. The CYP2D6 isoform is the most involved.

Berberine is safe in most clinical trials, but in small percentages, berberine has been reported to cause nausea, vomiting, constipation, hypertension, respiratory failure, and paresthesias. Overall, the intake of berberine, in doses of 500-1,000 mg/day, should be considered safe for most subjects. The risk of clinically relevant drug interaction due to the activity of berberine on the expression/activity of some isoenzymes of the CYP450 microsomal system is limited to cyclosporin and warfarin.

Berbevis is a new dietary ingredient consisting of berberine phospholipids. It is characterized by an optimized bioabsorption profile compared to unformulated berberine. The bio-absorption is optimized through the formulation of Berberis aristata extract with a specific Phytosome that increases its bio-accessibility and tolerability.

The ability of the Berberine Phytosome to positively support metabolic health was evaluated in a clinical study conducted on women with polycystic ovary syndrome (PCOS). After 60 days of administration of two 550 mg tablets of Berbevis, an improvement in the glycemic, lipid, and insulin resistance profiles was recorded.

Given this background, this study aimed to evaluate the potential benefit of oral intake of Berberine Phytosome in improving glycemic and lipid values in subjects with impaired fasting blood glucose (IFG).

Patients and Methods

Population

This study was a randomized, double-blind, placebo-controlled trial; it was conducted in overweight men and women with an IFG status (blood glucose between 6.1-7.0 mmol/L, glycosylated hemoglobin <7.0%), according to the American Diabetes Association. The subjects were recruited at the Dietetic and Metabolic Unit of the “Santa Margherita” Institute, University of Pavia, Italy.

Participants, without a history of cardiovascular disease (CVD) and liver, renal, and thyroid disorders, were not allowed to take any drugs likely affecting glucose or lipid metabolism (oral hypoglycemic agents and statins). Subjects with a habit of smoking and drinking more than two standard alcoholic beverages/day (20 g of alcohol/day) were excluded from the study. Physical activity was recorded, and sedentary subjects were admitted to the study. The Ethics Committee of the University of Pavia approved the protocol (ethical code Number: 0912/14122018), and it was registered at ClinicalTrials.gov under the registration number: NCT05031715. Written informed consent was obtained from all the volunteers.

Dietary Supplement

The dietary supplement was associated with one dose before main meals (lunch and dinner) of 550 mg of Berberine Phytosome (corresponding to 188 mg berberine). Subjects received the active or placebo for eight weeks.

Indena SpA (Milan, Italy) provided the tablets containing 550 mg of Berberine Phytosome.
(Berbevis™, Indena SpA, Milan, Italy) and the placebo. The latter was identical to active tablets in terms of size, shape, color, odor, and taste. Active and placebo film-coated tablets had a similar composition to inactive food-grade components. According to the Food Supplement European Regulation, before release, the film-coated tablets were verified for appearance, mass (average and uniformity), high-performance liquid chromatographic (HPLC) content of active compounds, disintegration time, and microbiological quality.

Compliance with the supplementation regimen was defined as the number of tablets taken by each subject, divided by the number of tablets that should have been taken throughout the study. Each treatment group was administered with indistinguishable products, with subjects assigned to each group according to a coded (A or B) block randomization table prepared by an independent statistician. Investigators were blinded to the randomization table, the code assignments, and the procedure. Independent of supplementation, the subjects followed a similar low-energy diet.

Adverse Events
All reports of any adverse events, by subjects and members of the research staff were registered. Moreover, routine blood biochemistry parameters (creatinine and liver function) were evaluated at the start and end of supplementation.

Glycemic and Lipidic Parameters
The glycemic and lipidic parameters were assessed at baseline (t₀, start of the study), after 30 days (t₁), and after 60 days (t₂, end of treatment). Blood samples were immediately centrifuged and frozen at -80°C until assayed. Fasting blood glucose (FBG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and triglyceride (TG) levels were measured by the automatic biochemical analyzer (Hitachi 747, Tokyo, Japan). The serum concentration of hemoglobin A1c (HbA1c) was determined by the HPLC method by an automated HbA1c analyzer (Tosoh HLC-723G7, Japan). The low detection limit was 10.7 pmol, and the intra- and inter-assay coefficients of variation were below 6%. Insulin resistance was evaluated after 12 hours of fasting. Furthermore, the subjects refrained from physical exercise for 48 hours before the blood sampling. The Homeostasis Model Assessment (HOMA) measured insulin resistance. Anthropometric Measurements and Dietary Counseling
Anthropometric measurements at baseline (t₀, start of the study), after 30 days (t₁), and after 60 days (t₂, end of supplementation) were assessed. A standardized technique was used to measure body weight and height, and the body mass index (BMI) was calculated (kg/m²).

Subjects restricted their daily energy intake by a moderate amount, 3,344 kJ/d less than daily requirements based on WHO criteria, with a regimen allowing a careful balance of macronutrients: 25-30% of energy from fat (cholesterol <200 mg), 55-60% of energy from carbohydrates (10% from simple carbohydrates), with 25 g of bran and 15-20% of energy from protein. A 3-day food record of two weekdays and one weekend day was performed during the first and the last week of the study. Participants compiled a three-day food record, including two weekdays and one weekend day during the first and last week of the study. Dietary records were analyzed using a food-nutrient database (Rational Diet, Milan, Italy).

Body Composition
The evaluation of Fat-Free Mass (FFM), Fat Mass (FM), gynoid, and android fat distribution was carried out through the dual-energy X-ray absorptiometry (DXA) with the use of a Lunar Prodigy DXA (GE Medical System, Boston, Massachusetts, United States). The in vivo coefficients of variants (CVs) were 0.89% and 0.48% for whole body fat (FM) and FFM, respectively. Visceral adipose tissue volume (VAT) was estimated using a constant correction factor (0.94 g/cm³). The software automatically places a quadrilateral box, which represents the android region, outlined by the iliac crest and with a superior height equivalent to 20% of the distance from the top of the iliac crest to the base of the skull.

Primary and Secondary Endpoints
The primary endpoint was glycemia, while secondary endpoints included: total cholesterol, HDL, total cholesterol/HDL, LDL, LDL/HDL, triglycerides, insulin, glycated hemoglobin, HOMA, ApoA, ApoB, ApoB/ApoA, androgen suppression treatment (AST), alternative lengthening of telomeres (ALT), gamma-glutamyl transferase (GGT), creatinine, waist circumference, VAT, fat,
and lean mass. All the endpoints were collected at three different time points (i.e., t₀, t₁, and t₂).

**Statistical Analysis**

Differences between groups at baseline were investigated in each continuous variable by using a t-test for independent data in normally distributed variables or the Wilcoxon test in non-normally distributed ones and using Chi-squared in categorical variables. Linear mixed models (LMM) were fitted with time, group, and the interaction time*group as a fixed effect, including a random result in the form of a subject to take into account for intra-subject correlation produced by the repeated measurements. This allowed for the evaluation of statistically significant changes over time for primary and secondary endpoints within and between the two groups. All the models were adjusted for age, sex, and BMI. The normality of residuals for each fitted model were assessed both graphically and via the Shapiro-Wilk test.

In the case of non-normality of LMM residuals, empirical bootstrap with 5,000 bootstrapped replicates was applied to estimate non-parametric 95% C.I.s and p-values based on distribution’s quantiles. The statistical significance is fixed as p-value ≤0.05.

Benjamini-Hochberg correction, fixing the False Discovery Rate (FDR) at α≤0.05, was used to account for multiple comparisons.

In the two groups at both t₀ and at t₂, Pearson’s pairwise partial correlations, adjusted for sex and age, were computed between i) the primary endpoint and each secondary endpoint, ii) LDL and each secondary endpoint, iii) VAT and each secondary endpoint, iv) BMI and each secondary endpoint, v) HOMA and each secondary endpoint and vi) fat mass and each secondary endpoint.

Descriptive statistics are reported as Mean ± Standard Deviation (SD). All the analysis was performed on R 3.5.1 statistical software using the nlme and stats packages (R Foundation for Statistical Computing, Vienna, Austria).

### Results

A total of 49 subjects, 28 females and 21 males, with a mean (±SD) age of (59.5±7.83), were randomly assigned to the supplemented group (n=24) and placebo (n=25), as reported in Table I. No statistically significant differences were observed between the supplemented and placebo groups at baseline parameters.

Table II reports the descriptive statistics regarding mean±SD for each endpoint measured in the two groups at t₀, after 30 days (t₁), and after 60 days (t₂).

Results of the within-group and between-group differences, adjusted for sex, age, and BMI, are reported respectively in Table III and Table IV, both for the primary and the secondary endpoints.

In regards to the within-group differences after multiple testing corrections (Table III), results showed a statistically significant decrease in glycemia [β=-0.37, 95% C.I. (-0.44; -0.29), p<0.0001], total cholesterol [β=-0.21, 95% C.I. (-0.39; -0.02), p=0.05], total cholesterol/HDL [β=-0.21, 95% C.I. (-0.37; -0.05), p=0.02], LDL/HDL [β=-0.12, 95% C.I. (-0.20; -0.04), p=0.01], insulin [β=-2.64, 95% C.I. (-3.44; -1.84), p<0.0001], HOMA [β=-0.91, 95% C.I. (-1.24; -0.57), p<0.0001], ApoB [β=-4.87, 95% C.I. (-8.73; -0.70), p=0.04], ApoB/ApoA [β=-0.06, 95% C.I. (-0.09; -0.03), p=0.0003], ALT [β=-1.17, 95% C.I. (-2.07; -0.26), p=0.02], waist circumference [β=-1.42, 95% C.I. (-2.10; -0.74), p=0.0003], VAT [β=-93.21, 95% C.I. (-127.11; -59.30), p<0.0001], and fat mass [β=-1.038.10, 95% C.I. (-1.408.94; -0.667.27), p<0.0001]. While in the placebo group, after multiple testing correction, the results showed after 60 days a statistically significant decrease of HOMA [β=-0.46, 95% C.I. (-0.70; -0.21), p<0.01] and glycated hemoglobin [β=-0.14, 95% C.I. (-0.24; -0.05), p=0.01], after 60 days of supplementation.

In regards to the between-group differences (Table IV), a statistically significant interac-

<p>| Table I. Mean (SD) at baseline (t₀) for age, BMI, and sex and p-value of the difference between the two groups. |
|-----------------------------------------------------|-----------------------------------------------------|-----------------|</p>
<table>
<thead>
<tr>
<th><strong>Supplemented (n = 24) mean (SD)</strong></th>
<th><strong>Placebo (n = 25) mean (SD)</strong></th>
<th><strong>p-value</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>58.83 (8.47)</td>
<td>60.20 (7.26)</td>
</tr>
<tr>
<td>BMI (Kg/m²)</td>
<td>30.16 (3.43)</td>
<td>29.47 (3.09)</td>
</tr>
<tr>
<td>Sex, N (%)</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Female</td>
<td>14 (56.00)</td>
<td>14 (58.33)</td>
</tr>
<tr>
<td>Male</td>
<td>10 (44.00)</td>
<td>11 (41.67)</td>
</tr>
</tbody>
</table>

BMI: Body Mass Index.
Results of all Pearson’s pairwise partial correlations adjusted for sex and age are reported in Supplementary Table I. Interestingly, high, positive statistically significant pairwise correlations were observed at t₂ between glycemia and insulin (r=0.62, p=0.002), glycemia and HOMA (r=0.68, p=0.0005), LDL and LDL/HDL (r=0.85, p<0.0001), LDL and ApoB (r=0.97, p<0.0001) LDL and ApoB/ApoA (r=0.81, p<0.0001), VAT and triglycerides (r=0.65, p=0.001), VAT and waist circumference (r=0.82, p<0.0001), VAT and fat mass (r=0.65, p=0.001), BMI and insulin (r=0.62, p=0.002), BMI and HOMA (r=0.62, p=0.002), BMI and waist circumference (r=0.85, p<0.0001), BMI and VAT (r=0.75, p<0.0001), BMI and fat mass (r=0.92, p<0.0001), HOMA and insulin (r=1, p<0.0001), HOMA and fat mass (r=0.71, p=0.0002), fat mass and insulin (r=0.73, p=0.0001), fat mass and waist circumference (r=0.74, p<0.0001) in the supplemented group. At t₂ in the supplemented group, high, positive, statistically significant pairwise correlations were observed at t₂ between glycemia and insulin (r=0.62, p=0.002), glycemia and HOMA (r=0.68, p=0.0005), LDL and LDL/HDL (r=0.85, p<0.0001), LDL and ApoB (r=0.97, p<0.0001) LDL and ApoB/ApoA (r=0.81, p<0.0001), VAT and triglycerides (r=0.65, p=0.001), VAT and waist circumference (r=0.82, p<0.0001), VAT and fat mass (r=0.65, p=0.001), BMI and insulin (r=0.62, p=0.002), BMI and HOMA (r=0.62, p=0.002), BMI and waist circumference (r=0.85, p<0.0001), BMI and VAT (r=0.75, p<0.0001), BMI and fat mass (r=0.92, p<0.0001), HOMA and insulin (r=1, p<0.0001), HOMA and fat mass (r=0.71, p=0.0002), fat mass and insulin (r=0.73, p=0.0001), fat mass and waist circumference (r=0.74, p<0.0001) in the supplemented group. At t₂ in the supplemented group, high, positive, statistically significant pairwise correlations were observed at t₂ between glycemia and insulin (r=0.62, p=0.002), glycemia and HOMA (r=0.68, p=0.0005), LDL and LDL/HDL (r=0.85, p<0.0001), LDL and ApoB (r=0.97, p<0.0001) LDL and ApoB/ApoA (r=0.81, p<0.0001), VAT and triglycerides (r=0.65, p=0.001), VAT and waist circumference (r=0.82, p<0.0001), VAT and fat mass (r=0.65, p=0.001), BMI and insulin (r=0.62, p=0.002), BMI and HOMA (r=0.62, p=0.002), BMI and waist circumference (r=0.85, p<0.0001), BMI and VAT (r=0.75, p<0.0001), BMI and fat mass (r=0.92, p<0.0001), HOMA and insulin (r=1, p<0.0001), HOMA and fat mass (r=0.71, p=0.0002), fat mass and insulin (r=0.73, p=0.0001), fat mass and waist circumference (r=0.74, p<0.0001) in the supplemented group. At t₂ in the supplemented group, high, positive, statistically significant pairwise correlations were observed at t₂ between glycemia and insulin (r=0.62, p=0.002), glycemia and HOMA (r=0.68, p=0.0005), LDL and LDL/HDL (r=0.85, p<0.0001), LDL and ApoB (r=0.97, p<0.0001) LDL and ApoB/ApoA (r=0.81, p<0.0001), VAT and triglycerides (r=0.65, p=0.001), VAT and waist circumference (r=0.82, p<0.0001), VAT and fat mass (r=0.65, p=0.001), BMI and insulin (r=0.62, p=0.002), BMI and HOMA (r=0.62, p=0.002), BMI and waist circumference (r=0.85, p<0.0001), BMI and VAT (r=0.75, p<0.0001), BMI and fat mass (r=0.92, p<0.0001), HOMA and insulin (r=1, p<0.0001), HOMA and fat mass (r=0.71, p=0.0002), fat mass and insulin (r=0.73, p=0.0001), fat mass and waist circumference (r=0.74, p<0.0001) in the supplemented group. At t₂ in the supplemented group, high, positive, statistically significant pairwise correlations were observed at t₂ between glycemia and insulin (r=0.62, p=0.002), glycemia and HOMA (r=0.68, p=0.0005), LDL and LDL/HDL (r=0.85, p<0.0001), LDL and ApoB (r=0.97, p<0.0001) LDL and ApoB/ApoA (r=0.81, p<0.0001), VAT and triglycerides (r=0.65, p=0.001), VAT and waist circumference (r=0.82, p<0.0001), VAT and fat mass (r=0.65, p=0.001), BMI and insulin (r=0.62, p=0.002), BMI and HOMA (r=0.62, p=0.002), BMI and waist circumference (r=0.85, p<0.0001), BMI and VAT (r=0.75, p<0.0001), BMI and fat mass (r=0.92, p<0.0001), HOMA and insulin (r=1, p<0.0001), HOMA and fat mass (r=0.71, p=0.0002), fat mass and insulin (r=0.73, p=0.0001), fat mass and waist circumference (r=0.74, p<0.0001) in the supplemented group. At t₂ in the supplemented group, high, positive, statistically significant pairwise correlations were observed at t₂ between glycemia and insulin (r=0.62, p=0.002), glycemia and HOMA (r=0.68, p=0.0005), LDL and LDL/HDL (r=0.85, p<0.0001), LDL and ApoB (r=0.97, p<0.0001) LDL and ApoB/ApoA (r=0.81, p<0.0001), VAT and triglycerides (r=0.65, p=0.001), VAT and waist circumference (r=0.82, p<0.0001), VAT and fat mass (r=0.65, p=0.001), BMI and insulin (r=0.62, p=0.002), BMI and HOMA (r=0.62, p=0.002), BMI and waist circumference (r=0.85, p<0.0001), BMI and VAT (r=0.75, p<0.0001), BMI and fat mass (r=0.92, p<0.0001), HOMA and insulin (r=1, p<0.0001), HOMA and fat mass (r=0.71, p=0.0002), fat mass and insulin (r=0.73, p=0.0001), fat mass and waist circumference (r=0.74, p<0.0001) in the supplemented group. At t₂ in the supplemented group, high, positive, statistically significant pairwise
Correlations were observed between LDL and total cholesterol ($r=0.89$, $p<0.0001$), LDL and LDL/HDL ($r=0.79$, $p<0.0001$), LDL and ApoB ($r=0.94$, $p<0.0001$), LDL and ApoB/ApoA ($r=0.80$, $p<0.0001$), VAT and waist circumference ($r=0.81$, $p<0.0001$), VAT and fat mass ($r=0.69$, $p=0.0003$), BMI and waist circumference ($r=0.86$, $p<0.0001$), BMI and VAT ($r=0.77$, $p<0.0001$), BMI and fat mass ($r=0.91$, $p<0.0001$), HOMA and insulin ($r=0.90$, $p<0.0001$), fat mass and insulin ($r=0.66$, $p=0.0009$), fat mass and waist circumference ($r=0.79$, $p<0.0001$). As for the control group, high, positive statistically significant pairwise correlations were observed at $t_0$ between VAT and waist circumference ($r=0.79$, $p<0.0001$), VAT and fat mass ($r=0.80$, $p<0.0001$), BMI and VAT ($r=0.79$, $p<0.0001$), BMI and fat mass ($r=0.89$, $p<0.0001$), HOMA and insulin ($r=1$, $p<0.0001$), while at $t_2$, high, positive statistically significant pairwise correlations were observed between VAT and fat mass ($r=0.79$, $p<0.0001$), BMI and VAT ($r=0.77$, $p<0.0001$), BMI and fat mass ($r=0.88$, $p<0.0001$), and HOMA and insulin ($r=0.90$, $p<0.0001$).

**Discussion**

The present study demonstrates the efficacy of a two-month-long supplementation of Berberine Phytosome™ on the metabolic profile and body composition of overweight subjects with IFG. In particular, a statistically significant improvement in the primary endpoint has been observed in the supplemented group; in fact, glycemia was significantly reduced, and considering the glycemic profile, insulin decreased. The lipid profile also improved in the supplemented group; total cholesterol levels, total/HDL cholesterol ratio, and triglycerides showed a statistically signifi-
cant reduction. Furthermore, ApoB/ApoA ratio decreased, which is an accurate risk factor for cardiovascular disease: the lower the ApoB/ApoA ratio, the lower the risk.

The results of our study agree with previous research, which has demonstrated that berberine was effective in modulating the glycemic profile. Zhang et al. showed that berberine increases insulin receptor expression and improves glucose utility both in vitro and in vivo models. The authors confirmed the activity of berberine in humans and its relationship with the glucose-lowering effect. Pérez-Rubio demonstrated that administration of 500 mg berberine three times a day leads to remission of metabolic syndrome and decreases in waist circumference, systolic blood pressure, triglycerides, and total insulin secretion, with an increase in insulin sensitivity, in subjects with metabolic syndrome. Nutraceutical supplements containing berberine, red yeast rice, coenzyme Q10, folic acid, and chrome were effective in improving lipid pattern and glucose levels in individuals with pre-hypertension. A more significant reduction of total cholesterol, LDL cholesterol, and glycemia was observed in the treatment group.

Moreover, berberine was effective in improving blood lipid levels (triglycerides, total cholesterol, LDL decreased, and HDL increased in the treatment group) in subjects with mild hyperlipidemia.

Oral administration of berberine significantly reduced body weight, and improved metabolic profile for lipid and glucose in patients with non-alcoholic fatty liver disease.

Another significant result of the present study is the positive changes observed in the body composition of the subjects supplemented with Berberine Phytosome. Specifically, VAT and fat mass were significantly reduced.

These results agree with a previous study in which the administration of 500 mg of berberine twice daily in PCOS women led to a statistically significant reduction of BMI, waist circumference, VAT, and fat mass, in addition to the improvements in HOMA values. Increasing evidence has shown that natural plant-based products may play a role in PCOS management.

Table IV. Between-group pre-post supplementation difference for primary and secondary endpoints. Estimate of time*treatment (β), 95% confidence interval (CI) and the adjusted p-value of the null hypothesis of a no effect are reported.

<table>
<thead>
<tr>
<th>Time*group β [95% CI]</th>
<th>p-value adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary endpoint</td>
<td></td>
</tr>
<tr>
<td>Glycemia (mmol/l)</td>
<td>-0.24 [-0.47; -0.06]</td>
</tr>
<tr>
<td>Secondary endpoint</td>
<td></td>
</tr>
<tr>
<td>Total Cholesterol (mmol/l)</td>
<td>-0.25 [-0.45; -0.04]</td>
</tr>
<tr>
<td>HDL (mmol/l)</td>
<td>0.03 [-0.02; 0.09]</td>
</tr>
<tr>
<td>Total Cholesterol/HDL</td>
<td>-0.25 [-0.43; -0.06]</td>
</tr>
<tr>
<td>LDL (mmol/l)</td>
<td>-0.08 [-0.21; 0.05]</td>
</tr>
<tr>
<td>LDL/HDL</td>
<td>-0.11 [-0.22; -0.003]</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>-0.14 [-0.25; -0.02]</td>
</tr>
<tr>
<td>Insulin (mcIU/ml)</td>
<td>-1.78 [-2.87; -0.66]</td>
</tr>
<tr>
<td>HOMA (pt)</td>
<td>-0.45 [-0.86; -0.04]</td>
</tr>
<tr>
<td>Glycated haemoglobin (%)</td>
<td>0.11 [-0.01; 0.25]</td>
</tr>
<tr>
<td>ApoA (mg/dl)</td>
<td>4.68 [-0.92; 10.40]</td>
</tr>
<tr>
<td>ApoB (mg/dl)</td>
<td>-6.83 [-12.27; -0.79]</td>
</tr>
<tr>
<td>ApoB/ApoA</td>
<td>-0.08 [-0.13; -0.03]</td>
</tr>
<tr>
<td>AST (IU/l)</td>
<td>-0.56 [-2.14; 1.17]</td>
</tr>
<tr>
<td>ALT (IU/l)</td>
<td>-1.35 [3.55; 1.29]</td>
</tr>
<tr>
<td>G-GT (U/l)</td>
<td>-0.55 [-2.57; 1.56]</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>0.01 [-0.01; 0.03]</td>
</tr>
<tr>
<td>Waist Circumference (cm)</td>
<td>-4.80 [-8.93; 0.30]</td>
</tr>
<tr>
<td>VAT (g)</td>
<td>-91.50 [-132.60; -48.19]</td>
</tr>
<tr>
<td>Fat Mass (g)</td>
<td>-945.56 [-1424.42; -441.57]</td>
</tr>
<tr>
<td>Lean Mass (g)</td>
<td>56.88 [-337.88; 451.63]</td>
</tr>
</tbody>
</table>

In bold are indicated the significant results (p ≤ 0.05). VAT: visceral adipose tissue; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; ApoB: Apolipoprotein B; ApoA: Apolipoprotein A; ALT: alanine aminotransferase; AST: aspartate aminotransferase; G-GT: Gamma-Glutamyl Transferase.
aim of this one-group pretest–post-test explanatory study was to evaluate, in normal–overweight PCOS women with normal menses, the effectiveness of berberine on: Insulin Resistance (IR).

The decrease in VAT is a positive result since it is associated with metabolic syndrome and cardiovascular disease, and it is also an independent risk factor of all-cause mortality. The management of VAT is a noteworthy result; in fact, VAT is considered equal to an endocrine organ capable of creating significant interactions between the brain, the liver, the skeletal muscle, the heart, and blood vessels.

All these results obtained (the statistically significant interaction between time and group on glycemia, total cholesterol, total cholesterol / HDL, triglycerides, insulin, ApoB / ApoA, VAT, fat mass, and the high positive statistically significant pairwise correlations observed), underline the pleiotropic activity of berberine on the metabolic profile. As discussed in a recent review by Feng et al., the significant inhibitory potency of Berberine against both α-amylase and α-glucosidase represents a possible explanation for its pleiotropic effect.

Laboratory tests were performed at baseline and end of treatment to test the safety of the product. No relevant adverse effects emerged. Thus, the present study has confirmed that berberine is well-tolerated with good compliance.

Limitations
The main limitations of this study are the small sample size and the relatively short duration of the intervention, which is only two months. Therefore, further studies with larger sample sizes and a longer period of intervention are needed to investigate further potential effects of berberine on the glycemic profile.

Conclusions
The results of this study are encouraging. In fact, in the supplemented group, both glycemia and insulin decreased. Moreover, the lipid profile improved, and total cholesterol levels, total/HDL cholesterol ratio, and triglycerides showed a statistically significant reduction. Even the ApoB/ApoA ratio decreased.

The administration of Berberine Phytosome did not result in side effects, supporting its potential use as a natural alternative to pharmacological therapies in the case of IFG.

Conflict of Interest
Authors GPet, PA, DA, and AR were employed by Indena SpA (Milan, Italy). The remaining authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contribution
Conceptualization, MR; methodology, MR and AR; validation, GPet, PA, DA, and AR; formal analysis, TF, and LB; data curation, ZP, FM, AT, and AC; writing-original draft preparation, MR; writing-review and editing, CG and GPer; project administration, MR. All authors have read and agreed to the published version of the manuscript.

Funding
This research did not receive external funding.

Ethics Approval
The study was conducted following the Declaration of Helsinki and approved by the Ethics Committee of the University of Pavia (ethical code Number: 0912/14122018).

Informed Consent
Informed consent was obtained from all subjects involved in the study.

ORCID ID
M. Rondanelli: 0000-0001-8336-4851
C. Gasparrri: 0000-0002-1088-6648
G. Petrangolini: 0000-0001-6681-7329
P. Allegrini: 0000-0002-4380-9577
T. Fazia: 0000-0002-9577-8450
L. Bernardinelli: 0000-0002-7551-6664
G. Peroni: 0000-0002-1632-1787
A. Tartara: 0000-0002-7480-0153
A. Riva: 0000-0003-2819-943X

References
4) Huang LH, Pan XP, Gong KR, Shao G. Anti-inflammatory effects of three kinds of tradition-


29) José Pinheiro S, Bates D, DebRoy S Sarkar D, Team R. Linear and Nonlinear Mixed Effects


